Therapeutic Compounds for Glaucoma via Aqueous Humor Outflow
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those involving ocular hypertensive conditions, often rely on topical β-adrenoreceptor antagonists and eicosanoids, which may not effectively manage intraocular pressure or have limitations in addressing the underlying causes of glaucoma, such as obstruction of aqueous humor outflow.
Innovation Solution
Development of compounds with specific structural features, including organic acid functional groups, amides, esters, and tetrazolyl functional groups, which can reduce intraocular pressure, treat glaucoma, and promote hair growth or improve hair appearance by targeting intraocular pressure, drainage issues, and ocular health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If topical β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but the underlying causes of glaucoma such as obstruction of aqueous humor outflow are not effectively addressed
Solution Approach 1:
The patent extracts and addresses the root cause of glaucoma by designing compounds that specifically target and improve aqueous humor outflow through the trabecular meshwork and canal of Schlemm, rather than merely suppressing symptoms. The compounds are structurally designed to interact with pathways involved in aqueous drainage, thereby extracting the underlying pathological mechanism from the symptom management approach.
Solution Approach 2:
Instead of continuing with the conventional approach of reducing intraocular pressure through β-adrenoreceptor antagonism, the patent inverts the therapeutic strategy by focusing on improving aqueous humor outflow through novel chemical structures that target drainage pathways directly, thereby addressing the problem from the opposite direction.
2Stress or pressure
If eicosanoids are used for glaucoma management, then intraocular pressure can be reduced, but limitations remain in effectively managing ocular hypertensive conditions
Solution Approach 1:
The patent creates compounds with universal applicability across different types of ocular hypertensive conditions including open-angle glaucoma, angle-closure glaucoma, and post-surgical hypertensive episodes. The chemical structures are designed to act through multiple mechanisms that can address various underlying causes, making the treatment versatile and adaptable to different clinical scenarios.
Solution Approach 2:
The patent employs parameter changes by modifying chemical structures with specific functional groups (carboxylic acids, amides, esters, tetrazolyl groups) and varying chain lengths and substitutions to optimize activity across different ocular conditions. This systematic variation of molecular parameters enables broad-spectrum effectiveness.
3Reliability
If traditional glaucoma treatments are used, then ocular health can be maintained, but additional benefits such as hair growth promotion are not achieved
Solution Approach 1:
The patent achieves multi-functionality by designing compounds that simultaneously provide ocular therapeutic effects (intraocular pressure reduction, glaucoma treatment) and extracocular benefits (hair growth promotion, hair appearance improvement). This single agent addresses multiple health concerns, expanding the therapeutic benefits beyond traditional glaucoma treatment.
Solution Approach 2:
The patent merges multiple therapeutic functions into a single compound class, combining glaucoma treatment capabilities with hair growth promotion effects. This consolidation allows one medication to address both ocular and dermatological conditions, reducing the need for multiple separate treatments.
Data Source
AI summary
A compound having a structureis disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.